Printed From:

PRALUENT® reduces the relative risk of MACE* by 15%1

In ODYSSEY OUTCOMES, on top of high-intensity/maximally tolerated statins, PRALUENT significantly reduced the risk of MACE vs placebo (HR 0.85, 95% CI 0.78, 0.93; p<0.001)1

*MACE defined in ODYSSEY OUTCOMES clinical trial as composite of coronary heart disease death, non-fatal myocardial infarction, fatal and non-fatal ischaemic stroke, or unstable angina requiring hospitalisation1
CI, confidence interval; CV, cardiovascular; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; MACE, Major adverse cardiovascular event; MI, myocardial infarction

References

  1. Schwartz GG et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018; 379:2097-2107.
  2. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/medicine/30956. Accessed March 2019.
   
Sanofi UK

Adverse events should be reported.

Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to Sanofi on 01483 554 242 or uk-drugsafety@sanofi.com.

SAGB.ALI.19.02.0295 | March 2019